Abstract:ABSTRACT In response to the ongoing COVID-19 pandemic, the quest for coronavirus inhibitors has inspired research on a variety of small proteins beyond conventional antibodies, including robust single-domain antibody fragments, i.e., “nanobodies.” Here, we explore the potential of nanobody engineering in the development of antivirals and diagnostic tools. Through fusion of nanobody domains that target distinct binding sites, we engineered multimodular nanobody constructs that neutralize wild-type SARS-CoV-2 and the Alpha and Delta variants at high potency, with IC 50 values as low as 50 pM. Despite simultaneous binding to distinct epitopes, Beta and Omicron variants were more resistant to neutralization by the multimodular nanobodies, which highlights the importance of accounting for antigenic drift in the design of biologics. To further explore the applications of nanobody engineering in outbreak management, we present an assay based on fusions of nanobodies with fragments of NanoLuc luciferase that can detect sub-nanomolar quantities of the SARS-CoV-2 spike protein in a single step. Our work showcases the potential of nanobody engineering to combat emerging infectious diseases. IMPORTANCE Nanobodies, small protein binders derived from the camelid antibody, are highly potent inhibitors of respiratory viruses that offer several advantages over conventional antibodies as candidates for specific therapies, including high stability and low production costs. In this work, we leverage the unique properties of nanobodies and apply them as building blocks for new therapeutic and diagnostic tools. We report ultra-potent SARS-CoV-2 inhibition by engineered nanobodies comprising multiple modules in structure-guided combinations and develop nanobodies that carry signal molecules, allowing rapid detection of the SARS-CoV-2 spike protein. Our results highlight the potential of engineered nanobodies in the development of effective countermeasures, both therapeutic and diagnostic, to manage outbreaks of emerging viruses.

Generation of Synthetic Acinetobacter baumannii-Specific Nanobodies

Characterization of a nanobody-epitope tag interaction and its application for receptor engineering

Exploiting human immune repertoire transgenic mice for protective monoclonal antibodies against antimicrobial resistant Acinetobacter baumannii

Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii

Discovery of Antimicrobial Peptides Targeting Acinetobacter Baumannii Via a Pre-Trained and Fine-Tuned Few-Shot Learning-Based Pipeline

Sequential Immune Acquisition of Monoclonal Antibodies Enhances Phagocytosis of Acinetobacter baumannii by Recognizing ATP Synthase

Development of nanobodies against Staphylococcus enterotoxin B through yeast surface display

Construction and validation of a synthetic phage-displayed nanobody library

A new generation of nanobody research tools using improved mass spectrometry-based discovery methods

Anti-Acinetobacter baumannii single-chain variable fragments show direct bactericidal activity

Sequence‐based design and construction of synthetic nanobody library

Deep Generative Design of Neutralizing Nanobodies Against SARS-CoV-2 Variants

Synthetic nanobodies as angiotensin receptor blockers.

Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons

A biosensor-based phage display selection method for automated, high-throughput Nanobody discovery

A Novel Approach to Development of Monoclonal Antibodies Using Native Antigen for Immunization and Recombinant Antigen for Screening.

Structural insights into the binding of nanobodies to the Staphylococcal enterotoxin B

Nanobody engineering for SARS-CoV-2 neutralization and detection

Nanobodies against SARS-CoV-2 RBD from a Two-step Phage Screening of Universal and Focused Synthetic Libraries

Integrated computer-aided drug design and biophysical simulation approaches to determine natural anti-bacterial compounds for Acinetobacter baumannii

Advancements in nanobody generation: Integrating conventional, in silico, and machine learning approaches